Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
19. Dezember 2024 08:30 ET
|
Evoke Pharma, Inc.
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical...
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
07. November 2024 16:05 ET
|
Evoke Pharma, Inc.
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52%...
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
19. September 2024 14:20 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
08. August 2024 08:30 ET
|
Evoke Pharma, Inc.
Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug....
Evoke Pharma, Inc. Announces Reverse Stock Split
30. Juli 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports First Quarter 2024 Financial Results
14. Mai 2024 16:15 ET
|
Evoke Pharma, Inc.
114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif.,...
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
07. März 2024 16:10 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an...
Evoke Pharma Reports Third Quarter 2023 Financial Results
09. November 2023 08:30 ET
|
Evoke Pharma, Inc.
38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year ...
Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
25. Juli 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., and CHICAGO, July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI)...
Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment
14. Juni 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...